IRVINE, Calif., April 16, 2014 /PRNewswire/ -- ChromaDex Corp. (OTCQB: CDXC), an innovative natural products company that provides proprietary ingredients and science-based solutions to the dietary supplement, food and beverage, animal health, cosmetic and pharmaceutical industries, announced today that its founder and CEO, Frank Jaksch, will speak at the 13th Annual Oxford International Conference on the Science of Botanicals on April 15th to 17th, 2014.
Mr. Jaksch, who will present on Wednesday, April 16, 2014, will speak to the challenges companies are facing regarding testing dietary supplement ingredients and finished products in order to comply with the FDA's final rule on current good manufacturing practice (cGMP) in manufacturing, packaging, labeling, or holding operations for dietary supplements.
The focus of the conference is to discuss approaches for post market surveillance, risk and safety assessment, quality control and adverse event reporting (AER) for botanical dietary supplements (BDS) and natural products, as well as regulatory aspects with perspectives from government, manufacturers and trade associations. To this end, the program will include relevant presentations from members of CFSAN/FDA, government officials, major trade associations and industry representatives discussing pressing topics that affect BDSs and their impact on consumers.
ChromaDex announced last October that its analytics laboratory located in Boulder, Colorado had received the internationally recognized ISO (International Organization for Standardization) and IEC (International Electrotechnical Commission) 17025:2005 accreditation, which demonstrates technical competence for a defined testing scope and the operation of a laboratory quality management system. This ISO/IEC 17025 accreditation was granted by ACLASS, an ANSI-ASQ National Accreditation Board agency.
ISO/IEC 17025 is the international standard by which a laboratory's commitment to quality is evaluated. ChromaDex achieved this accreditation by demonstrating technical competence for the testing of dietary supplements. Competence requirements include testing performed using standard and/or non-standard methods and laboratory-developed methods. ISO 17025 not only considers the management and technical expertise, but also emphasizes continuous process improvement.
ChromaDex is an innovative natural products company that discovers, acquires, develops and commercializes proprietary-based ingredient technologies through its unique business model that utilizes its wholly owned synergistic business units, including ingredient technologies, natural product fine chemicals (known as "phytochemicals"), chemistry and analytical testing services, and product regulatory and safety consulting (as Spherix Consulting). The company provides seamless science-based solutions to the nutritional supplement, food and beverage, animal health, cosmetic and pharmaceutical industries. The ChromaDex ingredient technologies unit includes products backed with extensive scientific research and intellectual property. Its ingredient portfolio includes pTeroPure® pterostilbene; ProC3G®, a natural black rice containing cyanidin-3-glucoside; PURENERGY™, a caffeine-pTeroPure co-crystal; and NIAGEN™, its recently launched branded nicotinamide riboside, a novel next-generation B vitamin. To learn more about ChromaDex, visit www.chromadex.com.
This release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities and Exchange Act of 1934, as amended. Statements that are not a description of historical facts constitute forward-looking statements and may often, but not always, be identified by the use of such words as "expects", "anticipates", "intends", "estimates", "plans", "potential", "possible", "probable", "believes", "seeks", "may", "will", "should", "could" or the negative of such terms or other similar expressions. Actual results may differ materially from those set forth in this release due to the risks and uncertainties inherent in the Company's business. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company's Annual Report on Form 10-K for the fiscal year ended December 28, 2013, the Company's Quarter Reports on Form 10-Q and other filings submitted by the Company to the SEC, copies of which may be obtained from the SEC's website at www.sec.gov. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement and the Company undertakes no obligation to revise or update this release to reflect events or circumstances after the date hereof.
ChromaDex Media Inquiries:
ChromaDex Company Contact:
Laura Kelly, Executive Assistant
SOURCE ChromaDex Corp.